DEVELOPING EUROPE & CIS

The main revenue contributor to our Developing Europe & CIS business is the Thrombosis portfolio. The Anaesthetics portfolio is anticipated to become a significant contributor in this region.

Key Countries

Czech Republic
Poland
Romania
Russia
Slovakia

Contribution to Group revenue

Revenue contribution - by therapeutic category

Injectable anticoagulants across Developing Europe & CIS grew 6,1% by volume. Volumes in Russia grew 15,6% over the same period.
Injectable anticoagulants across Developing Europe & CIS grew 6,1% by volume. Volumes in Russia grew 15,6% over the same period.

Source: May 2018 IMS

STATISTICS

Number of products launched:

Nil

(2017: 1)

IMS value of pipeline as at 30 June 2018 anticipated to be launched in:

0 – 2 years

USD4 million

3 – 5 years

USDnil

Number of product recalls:

Nil

(2017: nil)

Average staff turnover:

14,5%

(2017: 13,7%)

Number of work-related fatalities:

Nil

(2017: nil)

Number of permanent employees:

Revenue – R’billion	2018	2017 (CER)	% change
Total	2 780	2 611	6
Regional Brands	64	80	(20)
Anaesthetics	434	307	41
Thrombosis	1876	1760	7
High Potency & Cytotoxics	406	464	(13)